Clinical Trials Logo

Clinical Trial Summary

Investigate the safety and tolerability of umbilical cord-derived allogeneic mesenchymal stem cells to treat patients with Bradykinesia.


Clinical Trial Description

While the pathophysiological changes that result in the symptoms of bradykinesia are poorly understood, an inflammatory component appears to be involved. Human umbilical cord-derived allogeneic mesenchymal stem cells have documented anti-inflammatory properties, which suggest these cells may be effective at treating Bradykinesia. It is understood that perinatal products are potent immune modulators. It is believed that the positive symptomatic effects are secondary to the modulation of the immune system, and specifically the reduction in pathological inflammation. The study is designed to evaluate the safety and tolerability of umbilical cord-derived allogeneic mesenchymal stem cells to treat patients with Bradykinesia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04385056
Study type Interventional
Source IMAC Holdings, Inc.
Contact Christine Long
Phone 1 (844) 266-4622
Email contactus@imacregeneration.com
Status Recruiting
Phase Phase 1
Start date December 15, 2020
Completion date July 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT02046863 - Pilot Study for Automated Deep Brain Stimulation Programming N/A
Completed NCT04974034 - Movement Disorders Analysis Using a Deep Learning Approach
Not yet recruiting NCT05637593 - Rhythmic Auditory Stimulation on Upper-limb Movements in PD Patients N/A